Omeros (NASDAQ:OMER) Trading Up 6.9% – Here’s What Happened

Omeros Co. (NASDAQ:OMER)’s share price traded up 6.9% on Thursday . The company traded as high as $9.76 and last traded at $9.89. 149,168 shares changed hands during mid-day trading, a decline of 69% from the average session volume of 488,698 shares. The stock had previously closed at $9.25.

Analysts Set New Price Targets

A number of research analysts have recently commented on OMER shares. Needham & Company LLC restated a “hold” rating on shares of Omeros in a research report on Friday, January 17th. Rodman & Renshaw began coverage on shares of Omeros in a research report on Thursday, November 14th. They set a “buy” rating and a $9.00 price target for the company. Cantor Fitzgerald reissued a “neutral” rating on shares of Omeros in a research note on Thursday, November 14th. StockNews.com raised shares of Omeros from a “sell” rating to a “hold” rating in a research note on Wednesday, November 20th. Finally, RODMAN&RENSHAW raised shares of Omeros to a “strong-buy” rating in a research note on Thursday, November 14th. Three equities research analysts have rated the stock with a hold rating, two have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $22.50.

Omeros Stock Up 7.1 %

The firm’s 50-day moving average is $9.25 and its 200-day moving average is $6.69. The company has a market cap of $574.23 million, a PE ratio of -4.29 and a beta of 1.98.

Institutional Investors Weigh In On Omeros

A number of hedge funds and other institutional investors have recently bought and sold shares of OMER. Nomura Holdings Inc. lifted its stake in shares of Omeros by 136.2% in the fourth quarter. Nomura Holdings Inc. now owns 747,281 shares of the biopharmaceutical company’s stock worth $7,383,000 after buying an additional 430,932 shares in the last quarter. Susquehanna Fundamental Investments LLC purchased a new stake in shares of Omeros in the fourth quarter worth $1,488,000. Connor Clark & Lunn Investment Management Ltd. purchased a new position in Omeros during the fourth quarter valued at $1,120,000. Jacobs Levy Equity Management Inc. bought a new position in Omeros during the fourth quarter valued at $1,033,000. Finally, Ancora Advisors LLC lifted its position in Omeros by 1,036.4% during the fourth quarter. Ancora Advisors LLC now owns 85,800 shares of the biopharmaceutical company’s stock valued at $848,000 after purchasing an additional 78,250 shares during the last quarter. Hedge funds and other institutional investors own 48.79% of the company’s stock.

About Omeros

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.